Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis.
OBJECTIVE: The aim of this his study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals. METHODS: Retrospective cohort study that used registries and medical records from 2 different hosp...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| Repositorio: | r-FISABIO. Repositorio Institucional de Producción Científica |
| OAI Identifier: | oai:fisabio.fundanetsuite.com:p18526 |
| Acceso en línea: | https://fisabio.portalinvestigacion.com/publicaciones/18526 |
| Access Level: | acceso abierto |
| Palabra clave: | Estudio en vida real Persistence Persistencia Psoriasis Real-world Study Secukinumab |
| Sumario: | OBJECTIVE: The aim of this his study was to evaluate the real-world persistence, effectiveness, and safety of secukinumab in adult patients with moderate-to-severe psoriasis in two different hospitals. METHODS: Retrospective cohort study that used registries and medical records from 2 different hospitals (February 2015 to March 2024). Adults with moderate-to-severe psoriasis who initiated secukinumab treatment were identified and followed-up until March 2024, or disenrollment. Baseline demographic and clinical characteristics studied included sex, age at diagnóstico, weight, prior failed treatments, duration of treatment and psoriasis area severity index score (PASI). Adherence was measured using medication possession ratio (MPR); patients with MPR?more than?80% were considered adherent. Persistence, effectiveness, safety, and dosage regimen of secukinumab were collected. Kaplan-Meier analysis was used to estimate secukinumab persistence using 1-year intervals. RESULTS: A total of 88 patients with moderate-to-severe psoriasis were included, of whom 45 (51.1%) had not received prior biological treatment. Baseline PASI score was 15.0?±?2.9 and patients received 1.4?±?0.8 prior biological treatments. The most common previous biological treatments included anti-TNFa (60.5%) and ustekinumab (20.9%). Thirty-four (38.6%) patients discontinued secukinumab treatment due to the following reasons. Nineteen (21.5%) due to a lack of effectiveness, 8 (9.2%), due to achieve only a partial response and 7 (7.9%) due to adverse effects. Secukinumab persistence was 61.5?±?21.7 months for all patients. When performing a subgroup analysis, non-naïve patients obtained a persistence of 61.5?±?12.4 months followed by 54.1?±?14.8 months for naïve patients (p?=?0.804). Secukinumab persistence at 1?year, 2?years and 3?years was 72.7, 51.1 and 39.8%, respectively. CONCLUSIONS: Secukinumab demonstrated persistence in more than 70% of patients with moderate to severe psoriasis after the first year of treatment. |
|---|